Patients with CML in the lymphoid blastic phase have inferior response to anti-CD19 CAR T-cell therapy compared to de novo Ph-positive B cell acute lymphoblastic leukemia

被引：0
|
作者：
Liu, Mei-Jing [1 ,2 ]
Tan, Kai-Wen [1 ,2 ]
Cao, Han-Yu [1 ,2 ]
Huang, Si-Man [1 ,2 ]
Qian, Chong-Sheng [1 ,2 ]
Xue, Sheng-Li [1 ,2 ]
Dai, Hai-Ping [1 ,2 ]
Gong, Wen-Jie [1 ,2 ]
机构：
[1] First Affiliated Hosp Soochow Univ, Jiangsu Inst Hematol, Natl Clin Res Ctr Hematol Dis, Suzhou 215006, Peoples R China
[2] Soochow Univ, Inst Blood & Marrow Transplantat, Collaborat Innovat Ctr Hematol, Suzhou, Peoples R China
来源：
HEMASPHERE | 2024年 / 8卷 / 02期
关键词：
FOLLOW-UP; DASATINIB; EFFICACY;
D O I：
10.1002/hem3.49
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [21] CD19 CAR T-cell therapy in relapsed TCF3-HLF-positive B-cell acute lymphoblastic leukemia
    Yao, Yao
    Zhou, Jin
    Li, Yanting
    Shi, Sensen
    Yu, Lei
    Wu, Depei
    Wang, Ying
    ANNALS OF HEMATOLOGY, 2024, : 6031 - 6033
  • [22] Clinical outcomes of patients with lymphoid blastic phase of chronic myeloid leukemia treated with CAR T-cell therapy
    Liu, Yujie
    Tu, Yuqing
    Xiao, Jinyan
    Shen, Yifan
    Zhou, Biqi
    Yang, Qiannan
    Yu, Lei
    Qi, Lijuan
    Chen, Jia
    Liu, Tianhui
    Wu, Depei
    Xu, Yang
    BLOOD CANCER JOURNAL, 2024, 14 (01)
  • [23] Clinical outcomes of patients with lymphoid blastic phase of chronic myeloid leukemia treated with CAR T-cell therapy
    Yujie Liu
    Yuqing Tu
    Jinyan Xiao
    Yifan Shen
    Biqi Zhou
    Qiannan Yang
    Lei Yu
    Lijuan Qi
    Jia Chen
    Tianhui Liu
    Depei Wu
    Yang Xu
    Blood Cancer Journal, 14
  • [24] The influence of CRS and ICANS on the efficacy of anti-CD19 CAR-T treatment for B-cell acute lymphoblastic leukemia
    Ma, Yuhan
    Zhou, Hongyuan
    Zhang, Jiaoli
    Zhang, Qing
    Li, Yujie
    Xie, Ruiyang
    Zhang, Bingpei
    Shen, Ziyuan
    Li, Ping
    Liang, Aibin
    Zhou, Keshu
    Han, Lu
    Hu, Yongxian
    Xu, Kailin
    Sang, Wei
    Wang, Xiangmin
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [25] KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results
    Shah, Bijal D.
    Bishop, Michael R.
    Oluwole, Olalekan O.
    Logan, Aaron C.
    Baer, Maria R.
    Donnellan, William B.
    O'Dwyer, Kristen M.
    Holmes, Houston
    Arellano, Martha L.
    Ghobadi, Armin
    Pagel, John M.
    Lin, Yi
    Cassaday, Ryan D.
    Park, Jae H.
    Abedi, Mehrdad
    Castro, Januario E.
    DeAngelo, Daniel J.
    Malone, Adriana K.
    Mawad, Raya
    Schiller, Gary J.
    Rossi, John M.
    Bot, Adrian
    Shen, Tong
    Goyal, Lovely
    Jain, Rajul K.
    Vezan, Remus
    Wierda, William G.
    BLOOD, 2021, 138 (01) : 11 - 22
  • [26] Clinical Pharmacology and Determinants of Response to UCART19, an Allogeneic Anti-CD19 CAR-T Cell Product, in Adult B-cell Acute Lymphoblastic Leukemia
    Dupouy, Sandra
    Marchiq, Ibtissam
    Derippe, Thibaud
    Almena-Carrasco, Maria
    Jozwik, Agnieszka
    Fouliard, Sylvain
    Adimy, Yasmina
    Geronimi, Julia
    Graham, Charlotte
    Jain, Nitin
    Maus, Marcela V.
    Mohty, Mohamad
    Boissel, Nicolas
    Teshima, Takanori
    Kato, Koji
    Benjamin, Reuben
    Balandraud, Svetlana
    CANCER RESEARCH COMMUNICATIONS, 2022, 2 (11): : 1520 - 1531
  • [27] Maintenance therapy for early loss of B-cell aplasia after anti-CD19 CAR T-cell therapy
    Gabelli, Maria
    Oporto-Espuelas, Macarena
    Burridge, Saskia
    Chu, Jan
    Farish, Susan
    Hedges, Emma
    Ware, Kirsty
    Williams, Lindsey
    Young, Lindsey
    Alajangi, Rajesh
    Ancliff, Philip
    Bartram, Jack
    Bonney, Denise
    Chenchara, Lenka
    Chiesa, Robert
    Cugno, Chiara
    Hodby, Katharine
    Jalowiec, Katarzyna A.
    Lazareva, Arina
    Lucchini, Giovanna
    Mirci-Danicar, Oana C.
    Mullanfiroze, Khushnuma
    Pavasovic, Vesna
    Rao, Anupama
    Rao, Kanchan
    Riley, Lynne
    Samarasinghe, Sujith
    Shenton, Geoff
    Silva, Juliana
    Vora, Ajay
    Hough, Rachael
    Amrolia, Persis J.
    Ghorashian, Sara
    BLOOD ADVANCES, 2024, 8 (08) : 1959 - 1963
  • [28] Modeling Retreatment of Acute Lymphoblastic Leukemia with Anti-CD19 Chimeric Antigen Receptor T Cell Therapy
    Yang, Yinmeng
    Kohler, Mark Eric
    Fry, Terry J.
    BLOOD, 2016, 128 (22)
  • [29] Subsequent malignant neoplasms in patients previously treated with anti-CD19 CAR T-cell therapy
    Melody, Megan
    Epperla, Narendranath
    Shouse, Geoffrey
    Romancik, Jason
    Allen, Pamela
    Moyo, Tamara K.
    Kenkre, Vaishalee
    Ollila, Thomas
    Fitzgerald, Lindsey
    Hess, Brian
    David, Kevin
    Herr, Megan M.
    Odetola, Oluwatobi
    Lin, Adam
    Moreira, Jonathan
    Ma, Shuo
    Winter, Jane N.
    Roy, Ishan
    Stephens, Deborah
    Danilov, Alexey
    Shah, Nirav N.
    Barta, Stefan K.
    Cortese, Matthew
    Cohen, Jonathon B.
    Gordon, Leo I.
    Karmali, Reem
    BLOOD ADVANCES, 2024, 8 (10) : 2327 - 2331
  • [30] CD22 CAR T-cell therapy in refractory or relapsed B acute lymphoblastic leukemia
    Jing Pan
    Qing Niu
    Biping Deng
    Shuangyou Liu
    Tong Wu
    Zhiyong Gao
    Zhaoli Liu
    Yue Zhang
    Xiaomin Qu
    Yanlei Zhang
    Shaohui Liu
    Zhuojun Ling
    Yuehui Lin
    Yongqiang Zhao
    Yanzhi Song
    Xiyou Tan
    Yan Zhang
    Zhihui Li
    Zhichao Yin
    Bingzhen Chen
    Xinjian Yu
    Ju Yan
    Qinlong Zheng
    Xuan Zhou
    Jin Gao
    Alex H. Chang
    Xiaoming Feng
    Chunrong Tong
    Leukemia, 2019, 33 : 2854 - 2866
12345